Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases.

Autor:	Mesitskaya DF; Sechenov First Moscow State Medical University, Moscow, Russian Federation., Syrkin AL; Sechenov First Moscow State Medical University, Moscow, Russian Federation., Aksenova MG; Centre for the Strategic Planning and Management of Medical and Biological Health Risks, Moscow, Russian Federation., Zhang Y; Harbin Medical University, Harbin, China., Zamyatnin AA Jr; Sechenov First Moscow State Medical University, Moscow, Russian Federation.; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, 119992, Russian Federation., Kopylov PY; Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Jazyk:	angličtina
Zdroj:	Cardiovascular & hematological agents in medicinal chemistry [Cardiovasc Hematol Agents Med Chem] 2018; Vol. 16 (2), pp. 81-87.
DOI:	10.2174/1871525716666180724115132
Abstrakt:	Atherothrombosis-related diseases are one of the world's leading causes of mortality, and thus the search for new therapeutic approaches in this area remains a very urgent task. Modern pharmacogenomic technologies make it possible to obtain valuable data on disease pathogenesis and optimal therapeutic approaches. One promising research direction is the study of the thromboxane A2 - thromboxane A synthase - thromboxane A2 receptor axis. This review summarizes the recent evidence and suggests that systematic works in this area are creating new and promising opportunities in the treatment of patients with cardiovascular diseases. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu